Botulinum Toxin Therapy in Hidradenitis Suppurativa
- Registration Number
- NCT05403710
- Lead Sponsor
- University of Massachusetts, Worcester
- Brief Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
- Detailed Description
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description single group assignment Botulinum toxin men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa
- Primary Outcome Measures
Name Time Method Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment. 1-2 months after first treatment immune cell phenotyping
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Massachusetts Chan Medical School
🇺🇸Worcester, Massachusetts, United States